Allergan Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 214 Posts
1 2 3 ... 14
Undervalued Growth And Dividend Growth In Health Technology
Article By: Chuck Carnevale Wednesday, March 20, 2019 11:13 AM EDT
Although many Health Technology Sector companies have significantly outperformed the market on a long-term basis, they have significantly underperformed the market since the beginning of 2015.
In this article: ABBV, AGN, AMGN, BMY, BIIB, CELG, GILD, MYL, PFE, PRGO
Read
Wall Street's Top Stories For Tuesday, Jan. 29th
Article By: The Fly Tuesday, January 29, 2019 4:08 PM EDT
Stocks have mixed day as investors await Apple earnings.
In this article: AGN, EAT, GME, MMM, PCG, PFE, VZ, AAPL, SANM, WWD, FMCC, FNMA, SQ, OCX
Read
How Trump's Policies Moved Stocks - Dec. 23
Article By: The Fly Sunday, December 23, 2018 10:40 PM EDT
Trump accuses Facebook, Twitter, and Google of being "biased;" White House blocks tax break for alcohol companies.
In this article: BF-A, FB, GOOGL, GOOG, TWTR, DEO, STZ, BF-B, AGN, AZN, NVS
Read
5 Drug/Biotech Stocks Likely To Beat Q3 Earnings Estimates
Article By: Zacks Investment Research Sunday, October 28, 2018 2:00 PM EDT
There are a number of drug/biotech companies poised to surpass third-quarter estimates. However, given the large number of drug/biotech firms, the task of selecting stocks with possibilities to beat could appear quite daunting.
In this article: REGN, AGN, AMGN, ALNY, AMAG
Read
Allergan Says Study Of Higher Doses Of BOTOX Meets Primary Endpoint
Article By: The Fly Friday, September 14, 2018 8:09 PM EDT
Allergan announced clinical study results of higher doses of BOTOX Cosmetic compared to BOTOX Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines.
In this article: AGN
Read
Allergan Upgraded To Buy From Neutral At Mizuho
Article By: The Fly Friday, August 3, 2018 9:31 AM EDT
Mizuho analyst Irina Koffler upgraded Allergan to Buy and raised her price target for the shares to $210 from $194.
In this article: AGN
Read
Pharma Stock Roundup: Mixed Q1 For MRK, PFE, FDA Nod For Kymriah's 2nd Indication
Article By: Zacks Investment Research Friday, May 4, 2018 8:15 PM EDT
First-quarter results of pharma bigwigs like Pfizer, Merck and Allergan stole the limelight this week. Other than that, Novartis gained FDA approval for the second indication of its CAR-T therapy, Kymriah.
In this article: AGN, JNJ, MRK, NVS, PFE, UTHR, ABBV
Read
Allergan Beats Q1 Earnings, Stock Up
Article By: Zacks Investment Research Monday, April 30, 2018 12:09 PM EDT
Allergan’s first-quarter earnings of $3.74 per share were above our consensus estimate of $3.36 per share.
In this article: AGN
Read
Should You Buy Allergan Plc When Prices Drop?
Article By: Matthew Hogan Wednesday, April 4, 2018 4:37 PM EDT
Allergan plc investors have enjoyed seeing the stock price increase by 16.9% over the last month.
In this article: AGN
Read
Allergan Slides After Mylan, Revance Report Deal For Botox Biosimilar
Article By: The Fly Thursday, March 1, 2018 12:25 PM EDT
Shares of Allergan are under pressure this morning after Mylan and Revance Therapeutics announced an agreement for the development and commercialization of a proposed biosimilar to Botox.
In this article: AGN Also: MYL, RVNC
Read
Allergan: Europe Halts Esmya Prescriptions Amid Liver Risk Probe
Article By: Shock Exchange Friday, February 23, 2018 10:34 AM EDT
The European Medicines Agency advised that no new patients take Esmya due to potential links to liver injury. The decision could stymie AGN's attempt to seek FDA approval for Esmya in the U.S.
In this article: AGN Also: GEDRY, GEDSF
Read
IBB – Challenging 2016, Recovering 2017 And Resurgence In 2018
Article By: Noah Kiedrowski Tuesday, February 6, 2018 3:12 PM EDT
The Biotechnology cohort has finally notched a 52-week high and has made up much of the lost ground during the pummeling from both sides of the political isle during the 2016 presidential race.
In this article: AGN, JNJ, NVO, IBB, REGN, GILD, JUNO, ABBV, KITE
Read
Allergan Q4 Earnings Beat On Increase In Botox Sales
Article By: Zacks Investment Research Tuesday, February 6, 2018 1:00 PM EDT
Allergan plc’s fourth-quarter 2017 earnings came in at $4.86 per share.
In this article: AGN Also: SHPG, MYL, SGYP
Read
Patent Losses Could Sink Allergan
Article By: Shock Exchange Monday, February 5, 2018 9:04 AM EDT
Allergan reports Q4 earnings on Tuesday. The company faces patent losses for Restasis, Combigan and Estrace. They represent a combined 15% of total revenue.
In this article: AGN Also: TEVA, MYL, NVS
Read
Allergan Upgraded To Overweight From Equal Weight At Barclays
Article By: The Fly Monday, January 29, 2018 6:49 AM EDT
Barclays analyst Douglas Tsao upgraded Allergan to Overweight and raised his price target for the shares to $230 from $220.
In this article: AGN
Read
Allergan Fires 1,000 In Hopes Of Halting Stock Slide
Article By: Tyler Durden Wednesday, January 3, 2018 1:01 PM EDT
Allergan said it plans to cut more than 1,000 jobs and eliminate an additional 400 currently open positions, as it works to cut costs in the face of new competition for its second most important drug, dry-eye treatment Restasis.
In this article: AGN
Read
1 to 16 of 214 Posts
1 2 3 ... 14